Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First GMP Warning Letter Reflects FDA's List Of Major Concerns

This article was originally published in The Tan Sheet

Executive Summary

FDA's first warning letter concerning dietary supplement good manufacturing practices advises Coats International Holdings to follow written procedures, improve documentation and conduct appropriate identity tests

You may also be interested in...



FDA 'Program Alignment' Means Inspections Consistency To Supplement Industry

Reports are common about ORA officials not being knowledgeable about the agency's supplement manufacturing and marketing regulations or familiar with the commodity of dietary supplements, but relying on drug or food product manufacturing regulations when they inspect supplement facilities.

Supplement Firms Confounded By Identity Testing Waiver Process

FDA says it has not received any petitions to request an exemption from the 100% supplement ingredient identity testing requirement. Food and drug attorneys say the hassle of preparing a petition for a waiver outweighs the potential benefits

Supplement Firms Confounded By Identity Testing Waiver Process

FDA says it has not received any petitions to request an exemption from the 100% supplement ingredient identity testing requirement. Food and drug attorneys say the hassle of preparing a petition for a waiver outweighs the potential benefits

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel